Table 3. Meta-analysis of overall survival, bone metastasis-free survival and nonskeletal metastasis-free survival.
|
No. of subjects
|
|||||
|---|---|---|---|---|---|
| Meta-analysis | Control | Treatment | Heterogeneity (P-value) | I2 (%) | HR (95% CI) |
| Overall survival | |||||
| Advanced breast cancer only | 456 | 458 | <0.001 | 82 | 0.71 (0.40, 1.26) |
| Adjuvant clodronate treatment | 827 | 826 | <0.001 | 91 | 0.75 (0.31, 1.82) |
| Bone metastasis-free survival | |||||
| Advanced breast cancer only | 388 | 392 | 0.044 | 63 | 0.68 (0.34, 1.36) |
| Adjuvant clodronate treatment | 827 | 826 | 0.037 | 70 | 0.68 (0.38, 1.23) |
| Nonskeletal metastasis-free survival | |||||
| Advanced breast cancer only | 321 | 326 | <0.001 | 88 | 0.95 (0.31, 2.91) |
| Adjuvant clodronate treatment | 827 | 826 | <0.001 | 89 | 0.89 (0.40, 1.98) |
CI=confidence interval; HR=hazard ratio.